Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells
Shaowei Qiu, Vipul Sheth, Chengcheng Yan, et al.
Blood (2023) Vol. 142, Iss. 6, pp. 574-588
Open Access | Times Cited: 16

Showing 16 citing articles:

Integrative single‐cell expression and functional studies unravels a sensitization to cytarabine‐based chemotherapy through HIF pathway inhibition in AML leukemia stem cells
Talía Velasco-Hernández, Juan L. Trincado, Meritxell Vinyoles, et al.
HemaSphere (2024) Vol. 8, Iss. 2
Open Access | Times Cited: 6
Tyrosine Kinase Inhibitor Therapy Enhances Stem Cells Profile and May Contribute to Survival of Chronic Myeloid Leukemiastem Cells
Simone Rocco, Alessandro Maglione, Valentina Schiavo, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 392-392
Open Access
SOHO State of the Art Updates and Next Questions | Combination Therapy in Chronic Myeloid Leukemia in Chronic Phase
Alessandro Nanni Costa, Massimo Breccia
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Off-label use of anlotinib in malignancies’ treatment: efficacy and management of adverse reactions
Guangli Wang, Yuling Wang, Changhao Jin, et al.
Pharmacological Reports (2025)
Open Access
CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors
Stein‐Erik Gullaksen, Maria Omsland, Mathias Brevik, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-10
Open Access
Stroma-driven horizontal transfer of TCA proteins mediates metabolic plasticity and imatinib resistance in leukemia
Katarzyna Piwocka, Piotr Chrościcki, Nikodem Kasak, et al.
Research Square (Research Square) (2025)
Closed Access
Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors
Alessandro Nanni Costa, Emilia Scalzulli, Ida Carmosino, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 2, pp. 189-202
Closed Access | Times Cited: 3
Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia
Sam Humphries, Danielle R. Bond, Zacary P. Germon, et al.
Clinical Epigenetics (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 7
How to improve treatment‐free remission eligibility in chronic myeloid leukaemia?
Alessandro Nanni Costa, Massimo Breccia
British Journal of Haematology (2023) Vol. 204, Iss. 2, pp. 434-448
Closed Access | Times Cited: 7
State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia
David Frankhouser, Russell C. Rockne, Lisa Uechi, et al.
Leukemia (2024) Vol. 38, Iss. 4, pp. 769-780
Open Access | Times Cited: 2
Arsenic trioxide regulates the glycolytic pathway to treat acute promyelocytic leukemia by inhibiting RPL22L1
Heran Cui, Yuanyang Ma, Shulin Han, et al.
Leukemia Research (2024) Vol. 144, pp. 107550-107550
Closed Access
Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia
Kana Kusaba, Tatsuro Watanabe, Keisuke Kidoguchi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 20, pp. 11093-11093
Open Access
Gene correction for sickle cell disease hits its prime
Sébastien Levesque, Daniel E. Bauer
Nature Biomedical Engineering (2023) Vol. 7, Iss. 5, pp. 605-606
Closed Access | Times Cited: 1
State-transition Modeling of Blood Transcriptome Predicts Disease Evolution and Treatment Response in Chronic Myeloid Leukemia
David Frankhouser, Russell C. Rockne, Lisa Uechi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia
Noor E. Verhagen, Jan J. Koenderink, Nicole M. A. Blijlevens, et al.
Pharmaceutics (2023) Vol. 15, Iss. 11, pp. 2535-2535
Open Access | Times Cited: 1
Food for thought (and CML survival)
Maiko Sezaki, Gang Huang
Blood (2023) Vol. 142, Iss. 6, pp. 502-504
Closed Access
Page 1

Scroll to top